Your browser doesn't support javascript.
loading
A drug screen with approved compounds identifies amlexanox as a novel Wnt/ß-catenin activator inducing lung epithelial organoid formation.
Costa, Rita; Wagner, Darcy E; Doryab, Ali; De Santis, Martina M; Schorpp, Kenji; Rothenaigner, Ina; Lehmann, Mareike; Baarsma, Hoeke A; Liu, Xueping; Schmid, Otmar; Campillos, Monica; Yildirim, Ali Önder; Hadian, Kamyar; Königshoff, Melanie.
Afiliação
  • Costa R; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Wagner DE; Institute of Virology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • Doryab A; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • De Santis MM; Department of Experimental Medical Sciences, Wallenberg Centre for Molecular Medicine, Faculty of Medicine, Stem Cell Centre, Lund University, Lund, Sweden.
  • Schorpp K; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Rothenaigner I; Pulmonary Aerosol Delivery, Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum München-German Research Center for Environmental Health, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Lehmann M; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Baarsma HA; Department of Experimental Medical Sciences, Wallenberg Centre for Molecular Medicine, Faculty of Medicine, Stem Cell Centre, Lund University, Lund, Sweden.
  • Liu X; Assay Development and Screening Platform, Institute for Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • Schmid O; Assay Development and Screening Platform, Institute for Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • Campillos M; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Yildirim AÖ; Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München-German Research Center for Environmental Health, Ludwig Maximilian University of Munich, University Hospital Großhadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Hadian K; Department of Molecular Pharmacology, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Königshoff M; Institute of Structural Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
Br J Pharmacol ; 178(19): 4026-4041, 2021 10.
Article em En | MEDLINE | ID: mdl-34089180
ABSTRACT
BACKGROUND AND

PURPOSE:

Emphysema is an incurable disease characterized by loss of lung tissue leading to impaired gas exchange. Wnt/ß-catenin signalling is reduced in emphysema, and exogenous activation of the pathway in experimental models in vivo and in human ex vivo lung tissue improves lung function and structure. We sought to identify a pharmaceutical able to activate Wnt/ß-catenin signalling and assess its potential to activate lung epithelial cells and repair. EXPERIMENTAL

APPROACH:

We screened 1216 human-approved compounds for Wnt/ß-catenin signalling activation using luciferase reporter cells and selected candidates based on their computationally predicted protein targets. We further performed confirmatory luciferase reporter and metabolic activity assays. Finally, we studied the regenerative potential in murine adult epithelial cell-derived lung organoids and in vivo using a murine elastase-induced emphysema model. KEY

RESULTS:

The primary screen identified 16 compounds that significantly induced Wnt/ß-catenin-dependent luciferase activity. Selected compounds activated Wnt/ß-catenin signalling without inducing cell toxicity or proliferation. Two compounds were able to promote organoid formation, which was reversed by pharmacological Wnt/ß-catenin inhibition, confirming the Wnt/ß-catenin-dependent mechanism of action. Amlexanox was used for in vivo evaluation, and preventive treatment resulted in improved lung function and structure in emphysematous mouse lungs. Moreover, gene expression of Hgf, an important alveolar repair marker, was increased, whereas disease marker Eln was decreased, indicating that amlexanox induces pro-regenerative signalling in emphysema. CONCLUSION AND IMPLICATIONS Using a drug screen based on Wnt/ß-catenin activity, organoid assays and a murine emphysema model, amlexanox was identified as a novel potential therapeutic agent for emphysema.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Beta Catenina Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Beta Catenina Idioma: En Ano de publicação: 2021 Tipo de documento: Article